1. Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy.
   Rama Soundararajan et al, 2019, Cancers (Basel) CrossRef
2. Programmed Death–Ligand 1 and Vimentin: A Tandem Marker as Prognostic Factor in NSCLC
   Julien Ancel et al, 2019, Cancers CrossRef
3. Theoretical Substantiation of Personalized (Target) Therapy of Testicular Germ Cell Tumors
   S. M. Potapov et al, 2020, Ukr. ž. med. bìol. sportu CrossRef
4. The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
   Giuseppe Lamberti et al, 2020, Cancers CrossRef
5. Reversal of Chemotherapy Resistance to Cisplatin in NSCLC by miRNA-195-5p via Targeting the FGF2 Gene
   Hao Wang et al, 2021, PGPM CrossRef
6. Clinical Impact of the Epithelial-Mesenchymal Transition in Lung Cancer as a Biomarker Assisting in Therapeutic Decisions
   Julien Ancel et al, 2020, Cells Tissues Organs CrossRef
7. null
   Eric Lewis et al, 2022 CrossRef